A5101608246- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Computational Drug Discovery Methods
- Gene expression and cancer classification
- RNA modifications and cancer
- Calcium signaling and nucleotide metabolism
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Microbial Metabolic Engineering and Bioproduction
- Bioinformatics and Genomic Networks
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Ferrocene Chemistry and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer-related Molecular Pathways
- Transgenic Plants and Applications
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Microwave-Assisted Synthesis and Applications
- Monoclonal and Polyclonal Antibodies Research
- Renal and related cancers
- Pharmacogenetics and Drug Metabolism
- PARP inhibition in cancer therapy
Jilin University
2022-2024
National Defense Medical Center
2024
The University of Texas MD Anderson Cancer Center
2012-2020
Fourth People's Hospital of Liaocheng
2017
Chongqing Medical University
2017
The University of Texas Health Science Center at Houston
2012-2013
Abstract Although treatment with immune checkpoint inhibitors provides promising benefit for patients cancer, optimal use is encumbered by high resistance rates and requires a thorough understanding of mechanisms. We observed that tumors treated PD-1/PD-L1 blocking antibodies develop through the upregulation CD38, which induced all-trans retinoic acid IFNβ in tumor microenvironment. In vitro vivo studies demonstrate CD38 inhibits CD8+ T-cell function via adenosine receptor signaling or...
Small cell lung cancer (SCLC) is one of the most aggressive forms cancer, with a 5-year survival <7%. A major barrier to progress absence predictive biomarkers for chemotherapy and novel targeted agents such as PARP inhibitors. Using high-throughput, integrated proteomic, transcriptomic, genomic analysis SCLC patient-derived xenografts (PDXs) profiled lines, we identified drug sensitivity determined their prevalence in patient tumors. In contrast breast ovarian inhibitor response was not...
Effective targeted therapies for small-cell lung cancer (SCLC), the most aggressive form of cancer, remain urgently needed. Here we report evidence preclinical efficacy evoked by targeting overexpressed cell-cycle checkpoint kinase CHK1 in SCLC. Our studies employed RNAi-mediated attenuation or pharmacologic blockade with novel second-generation inhibitor prexasertib (LY2606368), currently clinical trials. In SCLC models vitro and vivo, LY2606368 exhibited strong single-agent efficacy,...
Purpose: Drugs targeting DNA repair and cell-cycle checkpoints have emerged as promising therapies for small-cell lung cancer (SCLC). Among these, the WEE1 inhibitor AZD1775 has shown clinical activity in a subset of SCLC patients, but resistance is common. Understanding primary acquired mechanisms will be critical developing effective combinations.Experimental Design: sensitivity cell lines was correlated with baseline expression level 200 total or phosphorylated proteins measured by...
Chronic stress hormones promote EGFR inhibitor resistance in mutant non–small cell lung cancer.
Small cell lung cancer (SCLC) is a recalcitrant for which no new treatments have been approved in over 30 years. While molecular subtyping now guides treatment selection patients with non-small and other cancers, SCLC still treated as single disease entity. Using model-based clustering, we found two major proteomic subtypes of characterized by either high thyroid transcription factor-1 (TTF1)/low cMYC protein expression or cMYC/low TTF1. Applying "drug target constellation" (DTECT) mapping,...
Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options. We previously found that PARP overexpressed in SCLC and targeting reduces line tumor growth preclinical models. However, lines PI3K/mTOR pathway activation were relatively less sensitive to inhibition. In this study, we investigated the proteomic changes other pathways occur following PAPR inhibition and/or knockdown vitro vivo. Using reverse-phase protein array, proteins most significantly upregulated...
Post-ovariectomy (OVX) changes in hormones induce obesity and white adipose tissue (WAT) inflammation. Increased energy expenditure via WAT browning is a novel therapeutic strategy for treating obesity. Naringenin (NAR) reduces inflammation lipogenesis attenuates estrogen deficiency-associated metabolic disorders; however, its role remains unclear. We investigated NAR ability to inhibit vivo using rat model vitro 3T3-L1 adipocytes. significantly decreased the body weight mass of rats. O2...
There is a lot of evidence that oral hypoglycemic drugs work by affecting gut microbes, but the key strains responsible for this effect are not well known. Huang-Qi-Ling-Hua-San (HQLHS), composed Astragalus Membranaceus, Ganoderma lucidum, Inonotus obliquus, and Momordica charantia L., specially designed Chinese medicine formula to treat type 2 diabetes (T2D). In study, mouse model T2D induced high-fat diet streptozotocin was used explore mechanism HQLHS in improving hyperglycemia...
Identification of bimodally expressed genes is an important task, as with bimodal expression play roles in cell differentiation, signalling and disease progression. Several useful algorithms have been developed to identify from microarray data. Currently, no method can deal data next-generation sequencing, which emerging a replacement technology for microarrays.We present SIBER (systematic identification using RNAseq data) effectively identifying We evaluate several candidate methods...
Objective: Yinchen Sini decoction (YCSND), a traditional Chinese medicine (TCM) formula, plays crucial role in the treatment of liver disease. However, bioactive constituents and pharmacological mechanisms action remain unclear. The present study aimed to reveal molecular mechanism YCSND acute injury (ALI) using integrated network analysis metabolomics. Methods: Ultra-high-performance liquid chromatography coupled with Q-Exactive focus mass spectrum (UHPLC-QE-MS) was utilized identify...
Abstract Purpose: Despite a growing arsenal of approved drugs, therapeutic resistance remains formidable and, often, insurmountable challenge in cancer treatment. The mechanisms underlying remain largely unresolved thus, examples effective combinatorial or sequential strategies to combat are rare. Here, we present Differential Sensitivity Analysis for Resistant Malignancies (DISARM), novel, integrated drug screen analysis tool designed address this dilemma. Experimental Design: DISARM,...
6009 Background: The molecular landscape of OPCs and its association with neoplastic progression is largely unknown. We report the results high throughput DNA/RNA profiling from pts in Erlotinib Prevention Oral Cancer trial (EPOC), long-term prospective follow-up. Methods: performed next generation sequencing 201 cancer genes (MD Anderson T200 platform) 170 EPOC, RNA using HTG EdgeSeq Oncology Biomarker Panel containing 2,560 transcripts a subset 141 OPCs. 73 developed invasive OC during...
Background . Chronic renal failure (CRF) has become a global health problem and bears huge economic burden. FuShengong Decoction (FSGD) as traditional Chinese medicine multiple pharmacological effects. Objectives To understand the underlying molecular mechanism signaling pathway involved in FSGD treatment of CRF screen differentially expressed proteins rats with treated FSGD. Methods Thirty‐three male Sprague‐Dawley were randomly divided into control group, group. Differentially screened by...
Abstract Motivation: Identifying genes altered in cancer plays a crucial role both understanding the mechanism of carcinogenesis and developing novel therapeutics. It is known that there are various mechanisms regulation can lead to gene dysfunction, including copy number change, methylation, abnormal expression, mutation so on. Nowadays, all these types alterations be simultaneously interrogated by different assays. Although many methods have been proposed identify from single assay, no...
Abstract Introduction: Small cell lung cancer (SCLC) is the most lethal form of characterized by early metastasis and rapid development drug resistance. The protein kinase ataxia telangiectasia mutated Rad3 related (ATR) a vital regulator DNA damage response (DDR) pathway commonly upregulated in cancers with high background replication stress (RS) such as SCLC. Inhibition ATR has shown activity prior preclinical studies SCLC being invested Phase 1 clinical trial. We hypothesize that...
With increasing use of publicly available gene expression data sets, the quality is a critical issue for downstream analysis, signature development, and cross-validation sets. Thus, identifying reliable measurements by leveraging multiple mRNA platforms an important analytical task. In this study, we propose statistical framework selecting between modeling correlations levels using beta-mixture model. The model-based selection provides effective objective way to separate good probes from...
Abstract Small cell lung cancer (SCLC) is an aggressive form of cancer, notable for rapid emergence drug resistance following initial chemotherapy. Rates five-year overall survival are only 7% across all stages and one drug, topotecan, approved by the FDA recurrent SCLC. As a result, National Cancer Institute has named identifying novel vulnerabilities in SCLC as urgent area need. Increased expression, relative to non-small (NSCLC), numerous components DNA damage response (DDR) pathway,...
ABSTRACT Common mechanisms for p53 loss in cancer include expression of MDM2 or the human papilloma virus (HPV)-encoded E6 protein which both mediate degradation wild-type (WT) (p53α). Here, we show that two alternatively-spliced, functional, truncated isoforms (p53β and p53γ, containing exons 1-9 gene) can be markedly upregulated by pharmacologic genetic inhibition nonsense mediated decay (NMD), a regulator aberrant mRNA stability. These lack binding domain hence have reduced susceptibility...